CARY, NC — February 5, 2015 — Biologics, an integrated oncology services company, is pleased to announce that Biologics has been selected as a specialty pharmacy authorized to dispense Ibrance (palbociclib). Ibrance was approved by the U.S. Food and Drug Administration on February 3, 2015 to be used in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
Recognized for its high-touch patient care model, Biologics’ Oncology Pharmacy Services and Patient Access Services group provides a dedicated, clinically relevant team to support the clinical, financial and emotional needs of specific patient populations.
“This patient population, representing around 60% of the advanced breast cancer population, has been waiting for 10 years for a new, advanced first-line treatment,” said Dan Duffy, chief business development officer at Biologics. “We feel privileged to have been selected to be part of the limited network of specialty pharmacies who can supply this important drug for these patients, and look forward to supporting patients in accessing, affording and adhering to this new therapy.”
In addition to developing unique patient care plans that help support patient compliance, Biologics will perform benefits investigation, benefits verification and prior authorization services to help streamline access to therapy and alleviate the administration burden on providers. The team also helps facilitate copayment or coinsurance assistance for patients.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.
Pharmacy name: Biologics
Street address: 13000 Weston Parkway, Suite 105, Cary, NC 27513
Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.
Biologics is part of McKesson Life Sciences (formerly McKesson Specialty Health), a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.mckessonspecialtyhealth.com and www.biologicsinc.com.